Histone deacetylases (HDACs) play a key role in the regulation of gene expression and chromatin structure, and drugs targeting these enzymes might have an important impact in the treatment of human ...cancer. Herein, we report the characterization of (1H)-pyrroles as a new subfamily of HDAC inhibitors obtained by computational modeling of class-I human HDACs. From a functional standpoint, (1H)-pyrroles are powerful inductors of acetylation of histones H3 and H4, and restore the expression of growth-inhibitory genes. From a cellular view, these compounds cause a marked decrease in the viability of cancer cells in vitro and in vivo, associated with a cell-cycle arrest at G2/M and an inhibition of angiogenesis. Thus, (1H)-pyrroles emerge as a novel group of HDAC inhibitors with promising antitumoral features.
The aim of this work is to gain an understanding of the heterogeneity of the customers of service firms dedicated to personal care. This comes from their participation in the value co-creation ...process. We later analyze if the distribution of the satisfaction variable is the same between the previously-identified groups. This analysis is carried out via a latent class segmentation. The empirical research data was obtained from a sample of users of firms from the Spanish sector of hairdressing and aesthetics. This is mostly made up of young, self-employed entrepreneurs and microenterprises. 547 questionnaires were correctly completed and included in the study. The use of the customers’ involvement in value co-creating as a segmentation criteria resulted in the users being put into two groups. It was thus verified that there are differences in the distribution of the satisfaction variable between the two groups studied. The main contribution of the study stems from considering the value co-creation behavior as a valid criterion for the segmentation of customers of aesthetics and personal care services. This facilitates the decision-making related to the marketing policies of the firms in the sector.
The earthen architectural heritage and, in general, the built ensembles integrating the so called "vernacular architecture", have been repeatedly investigated for more than a century by ...archaeologists, architects, ethnologists, historians or geographers. During the last thirty years we can find a significant progress in the procedures for studying, cataloguing, protecting and watching over these cultural goods, which are representative of the diverse ways of inhabiting and constructing in the different regions of the world. However, currently there are few interventions in this kind of heritage that one can consider truly scientific, which is even more obvious in the case of the earthen buildings. In fact, the earth-built architectural heritage is one of the most fragile and endangered sections in the vernacular heritage, regardless of what we find barely developed up to now the essential intervention criteria. To go in depth regarding the essential features of this kind of architecture, identify its main values as cultural landscape shaper and emphasize the most important historiographical contributions on the subject are the main goals of this paper.
DI-058 Use of omalizumab in a tertiary level hospital Carbajo, F Cossio; Barbosa, C Martinez-Múgica; Manceñido, F Alvarez
European journal of hospital pharmacy. Science and practice,
03/2016, Letnik:
23, Številka:
Suppl 1
Journal Article
Recenzirano
BackgroundOmalizumab is used to treat poorly controlled, severe and immunoglobulin E (IgE) mediated asthma.PurposeTo check the appropriate prescribing practice, and to assess the effectiveness and ...safety of omalizumab.Material and methodsWe conducted a retrospective study from January 2014 to August 2015, including all patients treated with omalizumab. They were followed-up for 16 and 32 weeks when possible. Variables included sex, age, weight, IgE level, omalizumab dose and other medication used before and after therapy, prick test of commercial allergens, volume exhaled during the first second of forced expiration (FEV1 (%)), exhaled nitric oxide (FENO (ppb)), exacerbation needing oral corticosteroid use, hospital admissions, symptoms experienced during the day/night, adverse event due to omalizumab and concomitant diseases relevant for treatment outcomes.ResultsAbstract DI-058 Table 1Baseline characteristicsNo of patients15 (60% female)Median (Md) age (years)31 (8–75)Positive prick test (%)80Md IgE level (UI/mL)56 (51–5000) (IQR 195–1317)Md FEV1 (%)76 (43–100)Md FENO (ppb)45 (19–101)Exacerbations: <6/year/ ≥6/year (%)87/46Symptoms during the day versus night (%)93 vs 79Obstructive rhinitis (%)53High dose long acting β2 agonists (LABA) (%)100High dose inhaled corticosteroids (IC) (%)86.7Oral corticosteroids (OC) (%)53.3Nasal corticosteroids (NC) (%)66,7Oral antihistamines (AH) (%)40Dose of omalizumab was optimal according to the product information in 73.3% of patients. In 3 off-label cases, IgE level was too high. One patient was overweight.Week 16 analysis showed that 75% (n = 3) of patients with high level exacerbations had recorded no events during this period, except one, who did not improve until week 32 (baseline IgE 5000 UI/mL). FEV1 improved for 6 of 7 (85.7%) patients (Md 12; IQR 6.8–12,7; 95% CI -12.8 to 15.7). Moreover, IC, OC and LABA dose were reduced on 50%, 37.5% and 20%, respectively.Week 32 information was available for only 2 patients.Adverse events were observed in 30% of patients (hypotension, dyspnoea after the second dose which required treatment interruption, and check oppression).ConclusionWe observed good prescription adequacy and practice management for omalizumab, even if closer follow-up is necessary. Treatment was associated with a reduction in asthma exacerbations and IC, OC and LABA requirements in most patients, and it also showed an acceptable safety profile.No conflict of interest.